ARIAD Presents Updated Clinical Data on Brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer
GENEVA & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2015-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113), in patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial. The new results include an analysis of safety and efficacy for patients treated at select doses of brigatinib and an evaluation of intracranial central nervous system (CNS) antitumor activity.
The updated results were presented at the 2015 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland.
Phase 2 Dose Sub-Analysis
The data presented at ELCC focused on the 98 patients treated at doses of 90 mg/day (n=18), 90 mg/day for 1 week followed by escalation to 180 mg/day (n=32), and 180 mg/day (n=48) in the Phase 2 portion of the trial. All patients receiving these doses were evaluated for safety, and patients with ALK+ NSCLC (n=65) were evaluated for efficacy. The presentation at ELCC is based on patient data as of January 19, 2015 with a median follow-up of 40 weeks (range, 0.1 – 150+ weeks).
“The updated data on select doses from the Phase 1/2 trial show robust anti-tumor activity of brigatinib in patients with crizotinib-resistant ALK+ NSCLC, with responses now approaching one year,” stated Rafael Rosell, M.D., Director, Cancer Biology & Precision Medicine Program Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital in Barcelona, Spain. “Importantly, by starting at the 90 mg dose, we have seen a reduction of early-onset pulmonary events observed at the higher starting doses.”
Key data from the study update include:
Safety Summary
The most common adverse events (AEs) of any grade, regardless of treatment relationship, were nausea, diarrhea, and fatigue and were similar in incidence across all three dose-cohorts, as follows:
At 90 mg/day (n=18): nausea (44%), headache (44%), diarrhea (39%), fatigue (39%), cough (39%), and increased amylase (33%)
At 90 mg to 180 mg/day (n=32): diarrhea (44%), nausea (41%), fatigue (38%), headache (28%), cough (28%), and increased amylase (28%)
At 180 mg/day (n=48): nausea (63%), diarrhea (38%), fatigue (31%), headache (31%), cough (25%), and increased amylase (15%)
Serious AEs, regardless of treatment relationship, occurring in 4% or more patients, were dyspnea, hypoxia, and pneumonia, as follows:
At 90 mg/day (n=18): dyspnea (1 patient, 6%), hypoxia (2 patients, 11%), and pneumonia (2 patients, 11%)
At 90 mg to 180 mg/day (n=32): dyspnea (2 patients, 6%), hypoxia (1 patient, 3%), and pneumonia (1 patient, 3%)
At 180 mg/day (n=48): dyspnea (2 patients, 4%), hypoxia (2 patients, 4%), and pneumonia (2 patients, 4%)
As previously observed and reported, fewer early-onset pulmonary events, including dyspnea, hypoxia, and new pulmonary opacities, were reported with a starting dose of 90 mg (2/50 patients, 4%) vs. 180 mg (6/44 patients, 14%). Importantly, no early-onset pulmonary events were observed in the 32 patients started at 90 mg and escalated to 180 mg after 7 days.
Response Summary
The median time on study for patients dosed at 90 mg/day was 33.5 weeks (range, 0.7-150+ weeks), 50.3 weeks (range, 0.1-70+ weeks) for the 90 mg to 180 mg/day cohort, and 31.4 weeks (range, 0.1-135+ weeks) for the 180 mg/day cohort.
Brigatinib was active at each of the three dosing regimens with similar efficacy among the cohorts:
Objective response rate (ORR) among the 14 evaluable ALK+ NSCLC patients dosed at 90 mg/day was 79% (11 patients, 7 confirmed).
Among the 26 evaluable ALK+ NSCLC patients dosed at 90 mg/day for 1 week followed by 180 mg/day, ORR was 81% (21 patients, 19 confirmed), including 3 patients (12%) with a complete response (CR).
Among the 25 evaluable ALK+ NSCLC patients dosed at 180 mg/day, ORR was 68% (17 patients, 16 confirmed), including 2 patients (8%) with a CR.
Median duration of response was 11.2 months for the 90 mg/day cohort, not yet reached for the 90 mg to 180 mg/day cohort, and 9.2 months for the 180 mg/day cohort.
Median progression-free survival (PFS) was 12.9 months for the 90 mg /day cohort, not yet reached for the 90 mg to 180 mg/day cohort, and 11.1 months for the 180 mg/day cohort.
Phase 1/2 Analysis of CNS Antitumor Activity
A separate evaluation of the efficacy and safety of brigatinib in ALK+ NSCLC patients with intracranial CNS metastases at baseline was also presented at the ELCC meeting. In an independent central radiological review of brain Magnetic Resonance Imaging (MRI) scans, 49 of 79 ALK+ NSCLC patients in the Phase 1/2 trial were identified to have intracranial CNS metastases at baseline. Of these 49 patients, 16 had measurable intracranial CNS metastases (15 evaluable) and 33 patients had only non-measurable intracranial CNS metastases (30 evaluable).
AEs in patients with CNS metastases occurred at a similar incidence as in the broader study population.
In this post-hoc analysis of centrally reviewed brain MRI, brigatinib demonstrated intracranial CNS antitumor activity with responses in ALK+ NSCLC patients with intracranial CNS metastases at baseline.
Objective response rate (ORR) was 53% in evaluable patients with measurable lesions (n=15), including 1 (7%) CR.
In evaluable patients with non-measurable lesions (n=30), ORR defined as disappearance of all lesions was 30% (9 patients).
For patients with a response and at least one follow-up MRI scan (n=16), median (Kaplan-Meier [KM] estimate) duration of intracranial response was 18.9 months. For patients with a follow-up MRI scan (n=45), median (KM estimate) intracranial PFS was 22.3 months.
Median time on study for ALK+ NSCLC patients with intracranial CNS metastases at baseline was 56.1 weeks (range, 0.1-150+ weeks).
Pivotal Phase 2 ALTA Trial Enrolling Patients
A separate, pivotal global Phase 2 trial of brigatinib (AP26113) in patients with locally advanced or metastatic ALK+ NSCLC who have progressed on crizotinib continues to enroll patients. The ALTA (ALK in Lung Cancer Trial of AP26113) trial is designed to determine the safety and efficacy of AP26113 in refractory ALK+ NSCLC patients. The trial will enroll approximately 220 patients including those with brain metastasis. Patients are randomized 1:1 to receive either 90 mg of brigatinib once per day continuously or a lead-in dose of 90 mg/day for 7 days followed by 180 mg/day continuously.
“We are on track for full patient enrollment in the ALTA trial in the third quarter of this year,” stated Frank G. Haluska, M.D., Ph.D., senior vice president of clinical research and development and chief medical officer at ARIAD. “We are encouraged by the CNS anti-tumor activity, now exceeding 18 months in the Phase 1/2 brigatinib trial, and look forward to the evaluation of activity on brain metastasis in the ALTA trial.”
|
国创新药在EGFR ex20ins突变NSCLC国
作者：seacat、Tony
今年上半年，一篇题为《我妻之死》的文章，曾在网络上引发强烈关
求助下一步治疗方案
大家好，我父亲在2024年7月份确诊小细胞肺癌广泛期，在此之前，我父亲在2022年11月份
KRAS G12D: 安罗替尼+曲美替尼？
各位朋友请教一下：
基因检测靶点KRAS G12D, 目前单用安罗替尼，但安罗替尼有耐药迹
发现招募：局部晚期或转移性尿路上皮
招募：局部晚期或转移性尿路上皮癌患者
地点：山东大学齐鲁医院肿瘤内科
研究主题
病例分享/肿瘤晚期全耐药，特殊治疗
病例分享/肿瘤晚期全耐药，特殊治疗寻生机
晚期肿瘤常规方案全无效了怎么办？
显身卡
